IGHV-unmutated CLL (U-CLL) is associated with a higher progression risk compared to its IGHV-mutated counterpart (M-CLL) (13, 16), relating in part to higher capacity for BCR signaling in the former (17, 18). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.